Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation for treating porcine contagious pleuropneumonia and respiratory tract mixed infection and preparation method thereof

A compound preparation, the technology of pleuropneumonia, is applied in the directions of anti-inflammatory agents, respiratory diseases, non-central analgesics, etc., which can solve problems such as difficulty in controlling the disease and curing, economic losses for farmers, and untimely treatment, and achieve blood medicine. The effect of long-term concentration maintenance, strong drug penetration and strong killing ability

Active Publication Date: 2014-09-03
湖南尚成生物科技有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Porcine infectious pleuropneumonia is often associated with one or more of other respiratory diseases such as swine panting disease, haemophilus parasuis disease, pasteurellosis, reproductive and respiratory syndrome, bordetella bronchiseptica, streptococcal disease, etc. Mixed infections lead to complicated conditions and difficult diagnosis. If the treatment is not timely, the mortality rate will be higher
General drugs or unilateral drugs are difficult to control and cure the disease, causing serious economic losses to farmers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating porcine contagious pleuropneumonia and respiratory tract mixed infection and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] The compound preparation of the present embodiment comprises the following components: florfenicol 10g, azithromycin 5g, diclofenac sodium 2.5g, trimethoprim 3g, dimethylformamide 30g, polyvinylpyrrolidone 1g, a- Add 14 g of pyrrolidone, 20 g of propylene glycol, 0.04 g of dexamethasone, and absolute ethanol to 100 ml.

[0031] Described preparation method comprises the steps:

[0032] (1) Mix 20g of dimethylformamide and 10g of propylene glycol, add polyvinylpyrrolidone and a-pyrrolidone, heat to 50°C, add florfenicol, azithromycin, and sodium diclofenac in sequence, and stir until dissolved to obtain A liquid;

[0033] (2) Take 10g of dimethylformamide, 10g of propylene glycol and 10g of absolute ethanol to form a composite solvent, heat to 80°C, add trimethoprim and stir until dissolved to obtain liquid B;

[0034] (3) Combine liquid A and liquid B, add dexamethasone pre-dissolved with 3ml of absolute ethanol, add absolute ethanol to 100ml, filter, fill with nitrog...

Embodiment 2

[0036] The compound preparation of this embodiment comprises the following components: Florfenicol 20g, azithromycin 10g, diclofenac sodium 5g, trimethoprim 6g, dimethylformamide 30g, polyvinylpyrrolidone 2g, α-pyrrolidone 13g, 20g of propylene glycol, 0.08g of dexamethasone, and absolute ethanol were added to 100ml.

[0037] Described preparation method comprises the steps:

[0038] (1) Mix 20g of dimethylformamide and 10g of propylene glycol, add polyvinylpyrrolidone and a-pyrrolidone, heat to 55°C, add florfenicol, azithromycin, and sodium diclofenac in sequence, and stir until dissolved to obtain A liquid;

[0039] (2) Take 10g of dimethylformamide, 10g of propylene glycol and 10g of absolute ethanol to form a composite solvent, heat to 70°C, add trimethoprim and stir until dissolved to obtain liquid B;

[0040] (3) Combine liquid A and liquid B, add dexamethasone pre-dissolved with 4ml of absolute ethanol, add absolute ethanol to 100ml, filter, fill with nitrogen, and s...

Embodiment 3

[0042] The compound preparation of this embodiment contains the following components: Florfenicol 10g, azithromycin 5g, aminopyrine 4g, trimethoprim 3g, dimethylformamide 30g, polyvinylpyrrolidone 1g, N-methyl- 15g of 2-pyrrolidone, 20g of propylene glycol, 0.04g of dexamethasone, and add absolute ethanol to 100ml.

[0043] Described preparation method comprises the steps:

[0044] (1) Mix 20g of dimethylformamide and 10g of propylene glycol, add polyvinylpyrrolidone and N-methyl-2-pyrrolidone, heat to 60°C, add florfenicol, azithromycin, and aminopyrine in turn, and stir until Dissolved to obtain liquid A;

[0045] (2) Take 10g of dimethylformamide, 10g of propylene glycol and 10g of absolute ethanol to form a composite solvent, heat to 60°C, add trimethoprim and stir until dissolved to obtain liquid B;

[0046] (3) Combine liquid A and liquid B, add dexamethasone pre-dissolved with 2ml of absolute ethanol, add absolute ethanol to 100ml, filter, fill with nitrogen, and ster...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound preparation for treating porcine contagious pleuropneumonia and respiratory tract mixed infection; the preparation comprises the following components in dose: each 100ml compound preparation contains 5-20g of florfenicol, 3-10g of azithromycin, 2-6g of antisepsis synergist, 2-8g of antipyretic analgesic anti-inflammatory agent, 0.03-0.08g of glucocorticoid, 8-18g of stabilizer and the balance of organic solvent. The invention further provides a preparation method of the compound preparation. In the compound preparation, the antibacterial medicines and the symptomatic treatment medicines, which are highly sensitive to bacteria, are used and are compounded on the basis of treating both symptoms and root causes, therefore the compound preparation has excellent curative effect on porcine contagious pleuropneumonia and respiratory tract mixed infection diseases, is wide in antibacterial spectrum and high in cure rate, and is long-acting, efficient and stable.

Description

technical field [0001] The invention relates to the field of veterinary pharmaceutical preparations, in particular to a compound preparation for treating porcine infectious pleuropneumonia and respiratory mixed infection and a preparation method thereof. Background technique [0002] Porcine infectious pleuropneumonia is a respiratory infectious disease of pigs caused by Actinobacillus pleuropneumoniae, and it is also one of the five major infectious diseases internationally recognized as endangering the modern pig industry. Clinically, it was characterized by acute sepsis, fever, cough, and high degree of dyspnea. Necropsy lesions were characterized by bilateral pleuropneumonia, hemorrhagic and necrotizing pneumonia. Acute morbidity and death often occur, the incidence rate can reach 80%-100%, and the mortality rate is generally more than 50%. [0003] Porcine infectious pleuropneumonia is often associated with one or more of other respiratory diseases such as swine pantin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/7052A61K9/08A61P11/00A61P31/04A61P29/00A61K31/165A61K31/573A61K31/505A61K31/4152A61K31/196
Inventor 熊以宓曹典军谭武贵
Owner 湖南尚成生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products